Cholesterol ‘increases breast cancer drug’s resistance’April 21st, 2009 - 2:44 pm ICT by ANI
Washington, April 21 (ANI): A new study conducted by researchers at Georgetown University Medical Center (GUMC) has found that breast cancer cells that don’t respond to tamoxifen may be producing high amounts of cholesterol in order to provide a kind of shield against the drug.
The findings suggest that widely available statin drugs, which reduce cholesterol levels, may be useful for patients with tamoxifen-resistant breast cancer.
Alternatively new agents could be designed to inhibit the excess production of cholesterol by breast cancer cells, say the researchers.
“We have shown that if you inhibit the activity of either of two molecules that we identified in these resistant breast cancer cells, cholesterol production is reduced,” said the study’s lead author, Rebecca Riggins, PhD, a research assistant professor of oncology at GUMC’s Lombardi Comprehensive Cancer Center in Washington.
“We are now looking at whether these cells become re-sensitized once more to tamoxifen when cholesterol production is blocked, and our bet is that they do,” she added.
During the study, the researchers were trying to understand why some women with estrogen receptor-positive (ER+) invasive lobular breast cancer do not benefit as much from hormonal therapy such as tamoxifen when compared to women with other forms of ER+ breast cancer.
They have concluded that cholesterol production inside these cancer cells is one culprit.
Riggins said that cholesterol causes a number of important actions within a cell and there are two potential explanations as to why high levels of cholesterol might be related to tamoxifen resistance.
“One is that cholesterol is an essential part of the plasma membrane that surrounds all eukaryotic cells. A high level of cholesterol can make this membrane more rigid, impairing the ability of drugs to enter cells and thus altering how sensitive a cancer cell is to this type of drug treatment,” she said.
“A second possibility is that our tamoxifen-resistant breast cancer cells have increased amounts of cholesterol specifically in the mitochondria. Mitochondria supply a cell with energy, but they also are responsible for determining how a cell responds to a death signal.
“High levels of mitochondrial cholesterol can delay or block cell death. This is important because many cancer drugs, including tamoxifen, have been shown to induce breast cancer cell death through the mitochondria,” she added.
The study has been presented at the Annual Meeting of the American Association for Cancer Research (AACR). (ANI)
- Possible clues to tamoxifen resistance in breast cancer patients found - Mar 31, 2011
- Discovery shows statins could fight cancer - Sep 14, 2012
- New experimental drug slows down growth of ovarian cancer - Apr 16, 2011
- Key culprit in breast cancer metastasis identified - Feb 17, 2011
- Evidence of unusual drug-resistant breast tumours found - Oct 09, 2010
- Flower power may cut resistance to breast cancer drug tamoxifen - Feb 17, 2010
- Preventive use of breast cancer drugs urged - Mar 28, 2011
- New genetic signatures of breast cancer drug resistance identified - Jan 11, 2011
- Compound used to control cholesterol may also kill breast cancer - Feb 23, 2011
- Why Tamoxifen fails to work on some breast cancer patients - Feb 24, 2010
- Indian-origin scientist's finding offers hope for advanced cancer patients - Apr 06, 2011
- Chemo plus tamoxifen beneficial for some breast cancer patients - Dec 11, 2009
- Long-term tamoxifen use may up aggressive breast cancer risk - Aug 26, 2009
- Cough syrup may help predict breast cancer drug's effectiveness - Nov 20, 2010
- Red wine compound 'can give a boost to breast cancer treatment' - Feb 15, 2011
Tags: all eukaryotic cells, breast cancer, breast cancer cells, breast cancer drug, cancer cell, cholesterol levels, cholesterol production, comprehensive cancer center, excess production, georgetown university medical, gumc, invasive lobular breast cancer, lobular breast cancer, lombardi comprehensive cancer center, plasma membrane, research assistant professor, resistance one, resistant breast cancer, statin drugs, university medical center